Back to discover

Protein / target

Tyrosine-protein phosphatase non-receptor type 6

Encoded byPTPN6P29350Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
High-Quality Ligand
1
Research papers

Protein at a glance

Biological role

Transmembrane receptor protein tyrosine phosphatase

Strongest disease association

Lymphoma, Large B-Cell, Diffuse

Via encoding gene PTPN6 · Literature evidence · score 0.31

Research activity

Emerging research

1 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling pathways and fundamental physiological processes such as hematopoiesis.

View complete UniProt function annotation

Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling pathways and fundamental physiological processes such as hematopoiesis (PubMed:14739280, PubMed:29925997). Dephosphorylates and negatively regulate several receptor tyrosine kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their signaling activities (PubMed:21258366, PubMed:9733788). When recruited to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors such as immunoglobulin-like transcript 2/LILRB1, programmed cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors involved in immune regulation, initiates their dephosphorylation and subsequently inhibits downstream signaling events (PubMed:11907092, PubMed:14739280, PubMed:37932456, PubMed:38166031). Modulates the signaling of several cytokine receptors including IL-4 receptor (PubMed:9065461). Additionally, targets multiple cytoplasmic signaling molecules including STING1, LCK or STAT1 among others involved in diverse cellular processes including modulation of T-cell activation or cGAS-STING signaling (PubMed:34811497, PubMed:38532423). Within the nucleus, negatively regulates the activity of some transcription factors such as NFAT5 via direct dephosphorylation. Also acts as a key transcriptional regulator of hepatic gluconeogenesis by controlling recruitment of RNA polymerase II to the PCK1 promoter together with STAT5A (PubMed:37595871)

Subcellular location

CytoplasmNucleus
Domains and Gene Ontology detail (53)

Domains & features

SH2 1SH2 2Tyrosine-protein phosphatase

Gene Ontology

  • Calpha-beta T cell receptor complex
  • Ccell-cell junction
  • Ccytoplasm
  • Ccytosol
  • Cextracellular exosome
  • Cextracellular region
  • Cmembrane
  • Cnucleolus
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane
  • Cprotein-containing complex

595 aa · 68 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOCell-cycle regulationGOReceptor tyrosine kinase signallingUniProtImmune signallingUniProt · GOApoptosis & cell deathUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·negative regulation of cell population proliferation
  • ·positive regulation of cell population proliferation

Cell-cycle regulation

  • ·mitotic cell cycle
  • ·regulation of G1/S transition of mitotic cell cycle

Receptor tyrosine kinase signalling

  • ·Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling p…

Immune signalling

  • ·Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling p…
  • ·alpha-beta T cell receptor complex
  • ·cytokine-mediated signaling pathway
  • ·negative regulation of B cell receptor signaling pathway

Apoptosis & cell death

  • ·Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling p…
  • ·regulation of apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PTPN6

Gene-level evidence surfaced through the gene PTPN6that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Lymphoma, Large B-Cell, Diffuse
0.34Limited support

Somatic mutation evidence dominant · Open Targets 0.31

Lung carcinoma
0.32Limited support

Somatic mutation evidence dominant · Open Targets 0.20

Leukemia, Myeloid, Acute
0.30Limited support

Somatic mutation evidence dominant · Open Targets 0.21

Carcinoma, Hepatocellular
0.29Limited support

Somatic mutation evidence dominant · Open Targets 0.21

Breast Neoplasms
0.28Limited support

Somatic mutation evidence dominant · Open Targets 0.21

View evidence synthesis (5)
Lymphoma, Large B-Cell, DiffuseLimited support
0.34
agreement 0.170.50
Somatic mutation71%Literature29%

Open Targets aggregate 0.31 · 2 independent evidence families

Lung carcinomaLimited support
0.32
agreement 0.190.45
Somatic mutation56%Animal model40%Literature4%

Open Targets aggregate 0.20 · 3 independent evidence families

Leukemia, Myeloid, AcuteLimited support
0.30
agreement 0.140.46
Somatic mutation61%Literature39%

Open Targets aggregate 0.21 · 2 independent evidence families

Carcinoma, HepatocellularLimited support
0.29
agreement 0.130.45
Somatic mutation63%Literature37%

Open Targets aggregate 0.21 · 2 independent evidence families

Breast NeoplasmsLimited support
0.28
agreement 0.120.45
Somatic mutation65%Literature35%

Open Targets aggregate 0.21 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Lymphoma, Large B-Cell, Diffuse0.31
Autoimmune disorder of central nervous system0.28
Melanoma0.26
Leukemia, Myeloid, Acute0.21
Carcinoma, Hepatocellular0.21
Breast Neoplasms0.21
Leukemia, Lymphocytic, Chronic, B-Cell0.20
Lung carcinoma0.20
Esophageal Squamous Cell Carcinoma0.19
Urinary bladder carcinoma0.19

Tractability

Small moleculesEmerging

Feasibility evidence (high-quality ligand and med-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · High-Quality LigandSM · Med-Quality PocketAB · GO CC high confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

regulation of catalytic activityToxCast

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

1 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.